AC
EW icon

Andromeda Capital’s Edwards Lifesciences EW Stock Holding History

Andromeda Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-36,204
Closed -$397K – 118
2013
Q4 		$397K Buy
+36,204
New +$408K 0.05% 91

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Andromeda Capital's EW Position: Q1 2014 in Review

Andromeda Capital sold out of Edwards Lifesciences (EW) in Q1 2014, closing a stake of 36,204 shares — an estimated $397K sold.

Andromeda Capital first reported a position in EW in Q4 2013 and held it in 1 quarter. The position peaked at $397K in Q4 2013. 410 funds tracked by Wall St. Rank hold EW as of Q1 2014.

  • Andromeda Capital reported no remaining Edwards Lifesciences position as of Q1 2014 after selling out during the quarter.
  • Andromeda Capital sold 36,204 Edwards Lifesciences shares in Q1 2014, an estimated $397K.
  • Andromeda Capital first reported a position in Edwards Lifesciences in Q4 2013 and held it in 1 quarter.
  • Andromeda Capital's Edwards Lifesciences position peaked at $397K in Q4 2013.
  • 410 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2014.

Based on Andromeda Capital's 13F filing for Q1 2014, filed 15 May 2014.